adalimumab-aaty (Yuflyma) vs infliximab-qbtx (Ixifi)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab-aaty (Yuflyma)
Marketed by Celltrion
NCT03789292 · Phase 3 · completed
This randomized, double-blind Phase 3 equivalence trial compared CT-P17 (Yuflyma) with EU-approved Humira in 648 adults with active rheumatoid arthritis. The primary endpoint was ACR20 response at week 24, and equivalence required the confidence interval of the difference to fall inside predefined margins. ACR20 response was 82.7% in both groups; the 95% CI (-5.94 to 5.94) and the 90% CI (-4.98 to 4.98) were inside the margins, so equivalence was shown and the primary endpoint was met. Source: the peer-reviewed trial report (Kay 2021).
Reported efficacy
American College of Rheumatology(ACR)20 Response Rate at Week 24.: ACR20 response at week 24, CT-P17 vs EU-adalimumab (ITT): 82.7% (268/324) in both groups; treatment difference 95% CI -5.94 to 5.94 (margin -15 to 15%) and 90% CI -4.98 to 4.98 (margin -12 to 15%), both within the predefined equivalence margins (Kay 2021, Arthritis Res Ther). (met)
Result source: NCT03789292
infliximab-qbtx (Ixifi)
Marketed by Pfizer
NCT02222493 · Phase 3 · completed
This was a randomized, quadruple-blinded, active-controlled Phase 3 equivalence trial in 650 adults with rheumatoid arthritis taking methotrexate, comparing PF-06438179 with infliximab. The primary endpoint was ACR20 response at Week 14, a clinical disease-activity measure: 61.1% with PF-06438179 versus 63.5% with infliximab, and the reported 95% confidence interval for the difference (-9.92 to 5.11) met the equivalence criterion, indicating no meaningful difference between treatments. This is strong evidence from a well-powered, blinded, controlled trial with a hard clinical endpoint and a met primary comparison.
Reported efficacy
Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1 (Week 14): Period 1: PF-06438179 198/324 (61.1%) vs Period 1: Infliximab-EU Remicade (INX) 207/326 (63.5%) (met)
Result source: NCT02222493
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-aaty (Yuflyma) | infliximab-qbtx (Ixifi) |
|---|---|---|
| ACR20 | 82.7% vs 82.7%vs HumiraNCT03789292 | 61.1% vs 63.5%vs Infliximab-EU Remicade (INX)NCT0222249312 other results
|
| ACR50 | —Not reported | —Not reported |
| ACR70 | —Not reported | —Not reported |
| DAS28-CRP remission | —Not reported | —Not reported |
| HAQ-DI, change | —Not reported | —Not reported |
| Modified Sharp score, change | —Not reported | —Not reported |
ACR20
- adalimumab-aaty (Yuflyma)
- 82.7% vs 82.7%vs HumiraNCT03789292
- infliximab-qbtx (Ixifi)
- 61.1% vs 63.5%vs Infliximab-EU Remicade (INX)NCT02222493
12 other results
- 71.1% vs 64.3% NCT02222493
- 70.6% vs 64.3% NCT02222493
- 71.1% vs 68.5% NCT02222493
- 69.2% vs 68.5% NCT02222493
- 73.6% vs 70.6% NCT02222493
- 76.9% vs 70.6% NCT02222493
- 60.8% vs 64.1% NCT02222493
- 63.3% vs 65.3% NCT02222493
- 64.8% vs 65.6% NCT02222493
- 57.7% vs 61.7% NCT02222493
- 52.5% vs 58.3% NCT02222493
- 32.4% vs 37.1% NCT02222493
ACR50
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab-qbtx (Ixifi)
- —Not reported
ACR70
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab-qbtx (Ixifi)
- —Not reported
DAS28-CRP remission
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab-qbtx (Ixifi)
- —Not reported
HAQ-DI, change
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab-qbtx (Ixifi)
- —Not reported
Modified Sharp score, change
- adalimumab-aaty (Yuflyma)
- —Not reported
- infliximab-qbtx (Ixifi)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab-aaty (Yuflyma): 4 of 4 rows · infliximab-qbtx (Ixifi): 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab-aaty (Yuflyma) | infliximab-qbtx (Ixifi) |
|---|---|---|
| Dropout rate | 6.5%CT-P17 Subcutaneous(SC) (Adalimuma NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 4 more results—Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 1: CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 2: CT-P17 Maintenance NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 2: Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 | —Period 1: PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 5 more results—Period 2: INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 2: PF-06438179/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: INX/INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: INX/PF-06438179/PF-06438 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: PF-06438179/PF-06438179/ NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 |
| Discontinued due to AEs | 2.2%CT-P17 Subcutaneous(SC) (Adalimuma NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 4 more results—Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 1: CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 2: CT-P17 Maintenance NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 2: Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 | —Period 1: PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 5 more results—Period 2: INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 2: PF-06438179/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: INX/INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: INX/PF-06438179/PF-06438 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: PF-06438179/PF-06438179/ NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 |
| Serious AEs | —CT-P17 Subcutaneous(SC) (Adalimuma NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 4 more results—Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 3.7%Treatment 1: CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 2%Treatment 2: CT-P17 Maintenance NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 3.3%Treatment 2: Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 | 5%Period 1: PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 5 more results2.8%Period 2: INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 4.6%Period 2: PF-06438179/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 2.4%Period 3: INX/INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 4.8%Period 3: INX/PF-06438179/PF-06438 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 1.2%Period 3: PF-06438179/PF-06438179/ NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 |
| Most frequent reported AEs | upper respiratory tract infection 5.6% nasopharyngitis 5.2% injection site reaction 4.9% NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 show 2 more resultsneutropenia 5% upper respiratory tract infection 3.3% urinary tract infection 3% NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 neutropenia 5.3% alanine aminotransferase increased 4.6% leukopenia 4.6% NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 | alanine aminotransferase increased 5.9% infusion related reaction 5.9% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 5 more resultsinfusion related reaction 4.2% alanine aminotransferase increased 0% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 infusion related reaction 2.9% alanine aminotransferase increased 0% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 alanine aminotransferase increased 0% infusion related reaction 0% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 alanine aminotransferase increased 0% infusion related reaction 0% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 alanine aminotransferase increased 0% infusion related reaction 0% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab-aaty (Yuflyma)
show 2 more results
infliximab-qbtx (Ixifi)
show 8 more results
+ 41 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-aaty (Yuflyma)'s landscape · infliximab-qbtx (Ixifi)'s landscape